DK2964229T3 - Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren - Google Patents

Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren Download PDF

Info

Publication number: DK2964229T3
Authority: DK; Denmark
Prior art keywords: histamin; benzoimidazole; receptor; modulators; pyrimidine
Prior art date: 2013-03-06

Application number

DK14760540.6T

Other languages

English (en)

Inventor

Magali B Hickey

Stefan Horns

Susanne Lochner

Matteo Conza

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-06

Filing date

2014-03-06

Publication date

2020-01-27

2014-03-06 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2020-01-27 Application granted granted Critical

2020-01-27 Publication of DK2964229T3 publication Critical patent/DK2964229T3/da

Links

WTZRQYJHRXQWTK-UHFFFAOYSA-N 2-pyrimidin-2-yl-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C1=NC=CC=N1 WTZRQYJHRXQWTK-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Endocrinology (AREA)
Crystallography & Structural Chemistry (AREA)
Neurology (AREA)
Virology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Metallurgy (AREA)
Materials Engineering (AREA)
Obesity (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Oil, Petroleum & Natural Gas (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)

DK14760540.6T 2013-03-06 2014-03-06 Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren DK2964229T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201361773706P	2013-03-06	2013-03-06
US201361776260P	2013-03-11	2013-03-11
US201361784909P	2013-03-14	2013-03-14
PCT/US2014/021130 WO2014138368A1 (en)	2013-03-06	2014-03-06	Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor

Publications (1)

Publication Number	Publication Date
DK2964229T3 true DK2964229T3 (da)	2020-01-27

Family

ID=51488591

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK14760540.6T DK2964229T3 (da)	2013-03-06	2014-03-06	Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren

Country Status (38)

Country	Link
US (4)	US8859575B2 (da)
EP (2)	EP2964229B1 (da)
JP (1)	JP6471103B2 (da)
KR (1)	KR102230383B1 (da)
CN (1)	CN105025898B (da)
AU (1)	AU2014225675B2 (da)
BR (1)	BR112015021463A8 (da)
CA (1)	CA2903737C (da)
CL (1)	CL2015002434A1 (da)
CR (1)	CR20150435A (da)
CY (1)	CY1122545T1 (da)
DK (1)	DK2964229T3 (da)
DO (1)	DOP2016000027A (da)
EA (1)	EA201591648A1 (da)
ES (1)	ES2773543T3 (da)
GT (1)	GT201500243A (da)
HR (1)	HRP20200253T1 (da)
HU (1)	HUE047681T2 (da)
IL (1)	IL240247B (da)
JO (1)	JO3516B1 (da)
LT (1)	LT2964229T (da)
MX (1)	MX373874B (da)
MY (1)	MY180726A (da)
NZ (1)	NZ710640A (da)
PE (1)	PE20151536A1 (da)
PH (1)	PH12015501731B1 (da)
PL (1)	PL2964229T3 (da)
PT (1)	PT2964229T (da)
RS (1)	RS59909B1 (da)
SA (1)	SA515360981B1 (da)
SG (1)	SG11201507117XA (da)
SI (1)	SI2964229T1 (da)
SM (1)	SMT202000084T1 (da)
TW (1)	TWI617554B (da)
UA (1)	UA118754C2 (da)
UY (1)	UY35370A (da)
WO (1)	WO2014138368A1 (da)
ZA (1)	ZA201507351B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0710083A2 (pt)	2006-03-31	2011-08-02	Janssen Pharmaceutica Nv	entidade quìmica benzoimidazol-2-il pirimidina e pirazina, composição farmacêutica e uso destas
US9371311B2 (en)	2008-06-30	2016-06-21	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyrimidine derivatives
WO2014138368A1 (en)	2013-03-06	2014-09-12	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
EP2970271B1 (en)	2013-03-14	2017-11-08	Janssen Pharmaceutica NV	P2x7 modulators
TWI599567B (zh)	2013-03-14	2017-09-21	健生藥品公司	Ｐ２ｘ７調節劑
EP2970304B1 (en)	2013-03-14	2018-08-15	Janssen Pharmaceutica NV	P2x7 modulators
JO3509B1 (ar)	2013-03-14	2020-07-05	Janssen Pharmaceutica Nv	معدلات p2x7
CA2960972C (en)	2014-09-12	2023-10-03	Janssen Pharmaceutica Nv	P2x7 modulating n-acyl-triazolopyrazines
EP3191492B1 (en)	2014-09-12	2019-01-09	Janssen Pharmaceutica NV	P2x7 modulators
JP6827113B2 (ja)	2017-01-21	2021-02-10	広州白雲山漢方現代薬業有限公司ＧｕａｎｇｚｈｏｕＨａｎｆａｎｇＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
AU2019349962A1 (en)	2018-09-28	2021-03-18	Janssen Pharmaceutica Nv	Monoacylglycerol lipase modulators
PE20211773A1 (es)	2018-09-28	2021-09-08	Janssen Pharmaceutica Nv	Moduladores de monoacilglicerol lipasa
US11839663B2 (en)	2019-09-30	2023-12-12	Janssen Pharmaceutica Nv	Radiolabelled MGL pet ligands
BR112022019077A2 (pt)	2020-03-26	2022-12-27	Janssen Pharmaceutica Nv	Moduladores da monoacilglicerol lipase

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3005852A (en)	1959-12-22	1961-10-24	Gen Aniline & Film Corp	Production of sulfoxides and sulfones
GB1062357A (en)	1965-03-23	1967-03-22	Pfizer & Co C	Quinazolone derivatives
US3931195A (en)	1971-03-03	1976-01-06	Mead Johnson & Company	Substituted piperidines
US4191828A (en)	1976-04-14	1980-03-04	Richardson-Merrell Inc.	Process for preparing 2-(2,2-dicyclohexylethyl)piperidine
US4337341A (en)	1976-11-02	1982-06-29	Eli Lilly And Company	4a-Aryl-octahydro-1H-2-pyrindines
US4190601A (en)	1978-05-31	1980-02-26	Union Carbide Corporation	Production of tertiary amines by reductive alkylation
JPS6130576A (ja)	1984-07-24	1986-02-12	Ube Ind Ltd	２−アミノ−５−シアノピリミジンの製法
GB9410031D0 (en)	1994-05-19	1994-07-06	Merck Sharp & Dohme	Therapeutic agents
GB9422391D0 (en)	1994-11-05	1995-01-04	Solvay Interox Ltd	Oxidation of organosulphur compounds
BR9509985A (pt)	1995-12-12	1998-11-03	Omeros Med Sys Inc	Solução para irrigação e método para inibição de dor inflamação e esparmo
US5883105A (en)	1996-04-03	1999-03-16	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU704792B2 (en)	1996-04-03	1999-05-06	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5880140A (en)	1996-04-03	1999-03-09	Merck & Co., Inc.	Biheteroaryl inhibitors of farnesyl-protein transferase
EP0891357A1 (en)	1996-04-03	1999-01-20	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
US5939439A (en)	1996-12-30	1999-08-17	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
WO1998031369A1 (fr)	1997-01-16	1998-07-23	Sekisui Chemical Co., Ltd.	Preparations a usage externe a absorption percutanee
CA2277273C (en)	1997-01-17	2008-03-25	Merck & Co., Inc.	Integrin antagonists
US5945422A (en)	1997-02-05	1999-08-31	Warner-Lambert Company	N-oxides of amino containing pyrido 2,3-D! pyrimidines
AU724216B2 (en)	1997-04-07	2000-09-14	Merck & Co., Inc.	A method of treating cancer
GB9801231D0 (en)	1997-06-05	1998-03-18	Merck & Co Inc	A method of treating cancer
AU9663798A (en)	1997-10-06	1999-04-27	Warner-Lambert Company	Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
BR9908004A (pt)	1998-02-17	2001-12-18	Tularik Inc	Composto, composição e método para prevençãoou supressão de uma infecção viral
ATE274510T1 (de)	1998-06-19	2004-09-15	Chiron Corp	Glycogen synthase kinase 3 inhibitoren
PT1038875E (pt)	1999-03-25	2003-10-31	Synthon Bv	Derivados de imidazopiridina e processo para os preparar
PL206826B1 (pl)	1999-06-23	2010-09-30	Sanofi Aventis Deutschland	Podstawione benzimidazole
TWI279402B (en)	1999-08-20	2007-04-21	Banyu Pharma Co Ltd	Spiro compounds having NPY antagonistic activities and agents containing the same
US6372743B1 (en)	1999-09-30	2002-04-16	Neurogen Corporation	Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
HUP0202263A3 (en)	1999-12-27	2003-02-28	Japan Tobacco Inc	Benzimidazole, indole and imidazo-pyridine derivatives and pharmaceutical compositions containing them
DE10006453A1 (de)	2000-02-14	2001-08-16	Bayer Ag	Piperidylcarbonsäuren als Integrinantagonisten
AU5721301A (en) *	2000-04-24	2001-11-07	Teva Pharma	Zolpidem hemitartrate
RU2002131589A (ru) *	2000-04-24	2004-03-27	Тева Фамэситикл Индастрис Лтд. (Il)	Гемитартрат золпидема
CA2409762A1 (en)	2000-06-23	2002-01-03	Donald J.P. Pinto	Heteroaryl-phenyl substituted factor xa inhibitors
AU2001289615A1 (en)	2000-06-28	2002-01-08	Thromb-X N.V.	Pluripotent embryonic stem (es) cell lines, improved methods for their production, and their use for germ line transmission and for the generation of genetically modified animals
JP3507483B1 (ja)	2000-07-21	2004-03-15	シンジェンタパーティシペーションズアクチェンゲゼルシャフト	４，６−ジメトキシ−２−（メチルスルホニル）−１，３−ピリミジンの製造方法
WO2002020495A2 (en)	2000-09-06	2002-03-14	Chiron Corporation	Inhibitors of glycogen synthase kinase 3
EP1351686A2 (en)	2000-11-20	2003-10-15	Pharmacia Corporation	Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
AU2002258400A1 (en)	2001-02-16	2002-08-28	Tularik Inc.	Methods of using pyrimidine-based antiviral agents
MXPA03008143A (es)	2001-03-09	2005-08-16	Johnson & Johnson	Compuestos heterociclicos.
WO2002076438A2 (en)	2001-03-23	2002-10-03	Chugai Seiyaku Kabushiki Kaisha	Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
JP2004525150A (ja)	2001-03-30	2004-08-19	スミスクラインビーチャムコーポレーション	治療用化合物としてのピラゾロピリジン類の使用
WO2002089738A2 (en)	2001-05-08	2002-11-14	Yale University	Proteomimetic compounds and methods
AR035543A1 (es)	2001-06-26	2004-06-16	Japan Tobacco Inc	Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
AU2002363368B2 (en) *	2001-11-05	2007-12-13	Merck Patent Gmbh	Hydrazono-malonitriles
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
EP1472248A1 (en)	2002-01-17	2004-11-03	Eli Lilly And Company	Modulators of acetylcholine receptors
TWI270542B (en)	2002-02-07	2007-01-11	Sumitomo Chemical Co	Method for preparing sulfone or sulfoxide compound
US7314937B2 (en)	2002-03-21	2008-01-01	Eli Lilly And Company	Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
US7498349B2 (en)	2002-08-02	2009-03-03	Genesoft Pharmaceuticals, Inc.	Biaryl compounds having anti-infective activity
US20040127395A1 (en)	2002-09-06	2004-07-01	Desai Pragnya J.	Use of histamine H4 receptor modulators for the treatment of allergy and asthma
US20040132715A1 (en)	2002-09-06	2004-07-08	Dunford Paul J.	Method to treat allergic rhinitis
JP4596915B2 (ja)	2002-09-06	2010-12-15	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	チエノピロリルおよびフラノピロリル化合物並びにヒスタミンｈ４受容体リガンドとしてのそれらの使用
RU2005106274A (ru)	2002-09-06	2005-11-10	Янссен Фармацевтика, Н.В. (Be)	Гетероциклические соединения
EP1546115A4 (en)	2002-09-27	2010-08-04	Merck Sharp & Dohme	Substituted pyrimidines
TW200501960A (en)	2002-10-02	2005-01-16	Bristol Myers Squibb Co	Synergistic kits and compositions for treating cancer
US20040105856A1 (en)	2002-12-02	2004-06-03	Robin Thurmond	Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
AU2004235907B2 (en)	2003-05-05	2007-08-30	F. Hoffmann La-Roche Ag	Fused pyrimidine derivatives with CRF activity
CA2525547C (en)	2003-05-14	2012-07-03	Torreypines Therapeutics, Inc.	Compounds and uses thereof in modulating amyloid beta
SE0302116D0 (sv) *	2003-07-21	2003-07-21	Astrazeneca Ab	Novel compounds
WO2005039485A2 (en)	2003-08-13	2005-05-06	Chiron Corporation	Gsk-3 inhibitors and uses thereof
US7781595B2 (en)	2003-09-22	2010-08-24	S*Bio Pte Ltd.	Benzimidazole derivatives: preparation and pharmaceutical applications
US20050070527A1 (en)	2003-09-30	2005-03-31	Edwards James P.	Quinoxaline compounds
PT1673348E (pt)	2003-09-30	2009-05-11	Janssen Pharmaceutica Nv	Compostos de benzoimidazole
US7115646B2 (en)	2003-10-08	2006-10-03	Bristol Myers Squibb, Co.	Cyclic diamines and derivatives as factor Xa inhibitors
EP1679309A4 (en)	2003-10-24	2007-03-28	Ono Pharmaceutical Co	ANTISTRESS MEDICAMENT AND ITS MEDICAL USE
US8277831B2 (en)	2004-02-17	2012-10-02	Advanced Technologies And Regenerative Medicine, Llc.	Drug-enhanced adhesion prevention
EP1737297B1 (en)	2004-03-25	2012-12-19	Janssen Pharmaceutica NV	Imidazole compounds
US7960394B2 (en)	2004-05-31	2011-06-14	Banyu Pharmaceutical Co., Ltd.	Quinazoline derivative
CA2572218C (en)	2004-06-30	2013-06-11	Janssen Pharmaceutica, N.V.	Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents
CA2577947A1 (en)	2004-08-31	2006-03-09	Banyu Pharmaceutical Co., Ltd.	Novel substituted imidazole derivative
US7906528B2 (en)	2004-10-05	2011-03-15	Novartis International Pharmaceutical Ltd.	Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7381732B2 (en)	2004-10-26	2008-06-03	Bristol-Myers Squibb Company	Pyrazolobenzamides and derivatives as factor Xa inhibitors
US7442716B2 (en)	2004-12-17	2008-10-28	Merck Frosst Canada Ltd.	2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
CA2591724C (en)	2004-12-17	2014-08-05	Merck Frosst Canada Ltd.	2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors
WO2006102645A1 (en)	2005-03-24	2006-09-28	Janssen Pharmaceutica, N.V.	Biaryl derived amide modulators of vanilloid vr1 receptor
WO2007044085A2 (en)	2005-05-19	2007-04-19	Xenon Pharmaceuticals Inc.	Heteroaryl compounds and their uses as therapeutic agents
US8193206B2 (en)	2005-06-14	2012-06-05	Taigen Biotechnology Co., Ltd.	Pyrimidine compounds
JP5118029B2 (ja)	2005-06-14	2013-01-16	タイゲンバイオテクノロジーカンパニー，リミテッド	ピリミジン化合物
JP5121707B2 (ja)	2005-07-04	2013-01-16	ハイポイントファーマシューティカルズ，エルエルシー	新規医薬
CA2622372A1 (en)	2005-09-13	2007-03-22	Palau Pharma, S.A.	2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity
AR056560A1 (es)	2005-10-06	2007-10-10	Astrazeneca Ab	Pirrolopiridinonas como moduladores cb1
JP5301999B2 (ja)	2005-10-31	2013-09-25	メルク・シャープ・アンド・ドーム・コーポレーション	Ｃｅｔｐ阻害薬
WO2007063935A1 (ja)	2005-12-02	2007-06-07	Mitsubishi Tanabe Pharma Corporation	芳香族化合物
JP2009527508A (ja)	2006-02-24	2009-07-30	メルクフロストカナダリミテツド	２−（フェニル又は複素環）−１ｈ−フェナントロ［９，１０−ｄ］イミダゾール
ATE479678T1 (de)	2006-03-31	2010-09-15	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyridine als modulatoren des histamin-h4-rezeptors
BRPI0710083A2 (pt) *	2006-03-31	2011-08-02	Janssen Pharmaceutica Nv	entidade quìmica benzoimidazol-2-il pirimidina e pirazina, composição farmacêutica e uso destas
AU2007235578B2 (en)	2006-04-07	2011-07-14	Janssen Pharmaceutica N.V.	Indoles and benzoimidazoles as modulators of the histamine H4 receptor
WO2007120690A2 (en)	2006-04-10	2007-10-25	Janssen Pharmaceutica N.V.	Combination histamine h1r and h4r antagonist therapy for treating pruritus
EP2019675A4 (en)	2006-05-02	2011-03-02	Merck Frosst Canada Ltd	METHOD FOR THE TREATMENT OR PREVENTION OF NEOPLASIA
US20090209571A1 (en)	2006-05-18	2009-08-20	Bernard Cote	Phenanthrene derivatives as MPGES-1 inhibitors
WO2008008359A2 (en)	2006-07-11	2008-01-17	Janssen Pharmaceutica, N.V.	Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
US8779154B2 (en) *	2006-09-26	2014-07-15	Qinglin Che	Fused ring compounds for inflammation and immune-related uses
TW200904437A (en)	2007-02-14	2009-02-01	Janssen Pharmaceutica Nv	2-aminopyrimidine modulators of the histamine H4 receptor
AR069480A1 (es)	2007-11-30	2010-01-27	Palau Pharma Sa	Derivados de 2-amino-pirimidina
US8084466B2 (en)	2007-12-18	2011-12-27	Janssen Pharmaceutica Nv	Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
NZ603069A (en)	2008-06-12	2013-08-30	Janssen Pharmaceutica Nv	Use of histamine h4 antagonist for the treatment of post-operative adhesions
MY158927A (en)	2008-06-12	2016-11-30	Janssen Pharmaceutica Nv	Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
WO2010002774A1 (en)	2008-06-30	2010-01-07	Janssen Pharmaceutica Nv	Process for the preparation of substituted pyrimidine derivatives
EP2303869A2 (en) *	2008-06-30	2011-04-06	Janssen Pharmaceutica, N.V.	Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
WO2010025314A2 (en) *	2008-08-28	2010-03-04	The General Hospital Corporation	Prevention and treatment of itch with cysteine protease inhibition
IT1395963B1 (it) *	2009-06-04	2012-11-02	Rottapharm Spa	Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
TWI519533B (zh)	2010-11-01	2016-02-01	Ｌｇ生命科學有限公司	１－｛（２Ｓ）－２－胺基－４－［２，４－雙（三氟甲基）－５，８－二氫吡啶并［３，４－ｄ］嘧啶－７（６Ｈ）－基］－４－側氧丁基｝－５，５－二氟哌啶－２－酮酒石酸鹽之水合物
EP2465498A1 (en)	2010-11-23	2012-06-20	Faes Farma, S.A.	Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
WO2014138368A1 (en)	2013-03-06	2014-09-12	Janssen Pharmaceutica Nv	Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor

2014
- 2014-03-06 WO PCT/US2014/021130 patent/WO2014138368A1/en not_active Ceased
- 2014-03-06 HU HUE14760540A patent/HUE047681T2/hu unknown
- 2014-03-06 EP EP14760540.6A patent/EP2964229B1/en active Active
- 2014-03-06 JP JP2015561646A patent/JP6471103B2/ja not_active Expired - Fee Related
- 2014-03-06 CA CA2903737A patent/CA2903737C/en active Active
- 2014-03-06 EA EA201591648A patent/EA201591648A1/ru unknown
- 2014-03-06 EP EP19213615.8A patent/EP3660011A1/en not_active Withdrawn
- 2014-03-06 RS RS20200160A patent/RS59909B1/sr unknown
- 2014-03-06 US US14/199,634 patent/US8859575B2/en active Active
- 2014-03-06 PE PE2015001832A patent/PE20151536A1/es not_active Application Discontinuation
- 2014-03-06 MY MYPI2015702907A patent/MY180726A/en unknown
- 2014-03-06 LT LTEP14760540.6T patent/LT2964229T/lt unknown
- 2014-03-06 KR KR1020157026804A patent/KR102230383B1/ko not_active Expired - Fee Related
- 2014-03-06 PT PT147605406T patent/PT2964229T/pt unknown
- 2014-03-06 HR HRP20200253TT patent/HRP20200253T1/hr unknown
- 2014-03-06 JO JOP/2014/0074A patent/JO3516B1/ar active
- 2014-03-06 SI SI201431440T patent/SI2964229T1/sl unknown
- 2014-03-06 ES ES14760540T patent/ES2773543T3/es active Active
- 2014-03-06 MX MX2015011688A patent/MX373874B/es active IP Right Grant
- 2014-03-06 UY UY0001035370A patent/UY35370A/es unknown
- 2014-03-06 SM SM20200084T patent/SMT202000084T1/it unknown
- 2014-03-06 CN CN201480012369.2A patent/CN105025898B/zh not_active Expired - Fee Related
- 2014-03-06 NZ NZ710640A patent/NZ710640A/en not_active IP Right Cessation
- 2014-03-06 DK DK14760540.6T patent/DK2964229T3/da active
- 2014-03-06 PL PL14760540T patent/PL2964229T3/pl unknown
- 2014-03-06 SG SG11201507117XA patent/SG11201507117XA/en unknown
- 2014-03-06 TW TW103107723A patent/TWI617554B/zh not_active IP Right Cessation
- 2014-03-06 AU AU2014225675A patent/AU2014225675B2/en not_active Ceased
- 2014-03-06 BR BR112015021463A patent/BR112015021463A8/pt not_active Application Discontinuation
- 2014-06-03 UA UAA201509634A patent/UA118754C2/uk unknown
- 2014-08-21 US US14/465,677 patent/US9278952B2/en not_active Expired - Fee Related
2015
- 2015-07-30 IL IL240247A patent/IL240247B/en active IP Right Grant
- 2015-08-06 PH PH12015501731A patent/PH12015501731B1/en unknown
- 2015-08-24 CR CR20150435A patent/CR20150435A/es unknown
- 2015-08-31 CL CL2015002434A patent/CL2015002434A1/es unknown
- 2015-09-02 GT GT201500243A patent/GT201500243A/es unknown
- 2015-09-03 SA SA515360981A patent/SA515360981B1/ar unknown
- 2015-10-05 ZA ZA2015/07351A patent/ZA201507351B/en unknown
2016
- 2016-01-22 DO DO2016000027A patent/DOP2016000027A/es unknown
- 2016-02-18 US US15/047,359 patent/US9434715B2/en not_active Expired - Fee Related
- 2016-08-03 US US15/227,878 patent/US9663497B2/en not_active Expired - Fee Related
2020
- 2020-02-03 CY CY20201100085T patent/CY1122545T1/el unknown

Also Published As

Publication number	Publication date
SMT202000084T1 (it)	2020-03-13
AU2014225675A1 (en)	2015-08-13
UA118754C2 (uk)	2019-03-11
US20140364607A1 (en)	2014-12-11
CY1122545T1 (el)	2021-01-27
NZ710640A (en)	2019-03-29
CN105025898A (zh)	2015-11-04
US8859575B2 (en)	2014-10-14
US9434715B2 (en)	2016-09-06
CA2903737C (en)	2021-05-18
IL240247B (en)	2019-06-30
TWI617554B (zh)	2018-03-11
PL2964229T3 (pl)	2020-05-18
SA515360981B1 (ar)	2016-06-23
PE20151536A1 (es)	2015-10-28
WO2014138368A1 (en)	2014-09-12
JO3516B1 (ar)	2020-07-05
US20160159775A1 (en)	2016-06-09
JP6471103B2 (ja)	2019-02-13
CA2903737A1 (en)	2014-09-12
RS59909B1 (sr)	2020-03-31
ZA201507351B (en)	2017-08-30
DOP2016000027A (es)	2017-04-30
SI2964229T1 (sl)	2020-02-28
KR20150126881A (ko)	2015-11-13
PH12015501731A1 (en)	2015-10-19
KR102230383B1 (ko)	2021-03-23
HRP20200253T1 (hr)	2020-05-29
TW201516042A (zh)	2015-05-01
UY35370A (es)	2014-09-30
GT201500243A (es)	2015-11-18
HK1218513A1 (en)	2017-02-24
CN105025898B (zh)	2018-01-23
CL2015002434A1 (es)	2016-02-05
PT2964229T (pt)	2020-03-23
PH12015501731B1 (en)	2015-10-19
CR20150435A (es)	2015-11-02
SG11201507117XA (en)	2015-10-29
ES2773543T3 (es)	2020-07-13
US9278952B2 (en)	2016-03-08
US9663497B2 (en)	2017-05-30
US20140256942A1 (en)	2014-09-11
IL240247A0 (en)	2015-09-24
EP2964229A4 (en)	2016-11-16
LT2964229T (lt)	2020-02-10
BR112015021463A8 (pt)	2019-11-19
AU2014225675B2 (en)	2018-10-04
HUE047681T2 (hu)	2020-05-28
EP3660011A1 (en)	2020-06-03
MX373874B (es)	2020-03-26
MX2015011688A (es)	2015-12-07
JP2016510752A (ja)	2016-04-11
EP2964229A1 (en)	2016-01-13
BR112015021463A2 (pt)	2017-07-18
MY180726A (en)	2020-12-08
EA201591648A1 (ru)	2016-02-29
US20160340337A1 (en)	2016-11-24
EP2964229B1 (en)	2019-12-11

Publication	Publication Date	Title
DK2964229T3 (da)	2020-01-27	Benzoimidazol-2-yl-pyrimidinmodulatorer af histamin-h4 receptoren
IL245848B (en)	2020-08-31	Octahydro fused azadecalin glucocorticoid receptor modulators
DK3395814T3 (da)	2022-07-04	Hæmmere af fibroblastvækstfaktorreceptoren
DK2970954T3 (da)	2019-01-02	Modifikation af polypeptider
DK3087183T3 (da)	2020-09-14	Modulation af angiopoietin-3-lignende ekspression
DK2845905T3 (da)	2021-06-14	Fremstilling af oligosaccharider
HRP20182004T1 (hr)	2019-02-08	Tetrahidropiridopirazini modulatori gpr6
HUE049794T2 (hu)	2020-10-28	Új aminopirimidin származékok
DK3300500T3 (da)	2020-05-18	Triazolagonister af apj-receptoren
DK2954051T3 (da)	2019-07-08	Modificeret kapsid til genoverførsel til behandling af nethinden
EP2972579A4 (en)	2016-11-09	DIGITAL REGULATION OF THE EYE DISTANCE
DK2981255T3 (da)	2022-11-14	Terapeutiske anvendelser af empagliflozin
DK3083540T3 (da)	2020-02-24	Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK2961388T3 (da)	2019-07-08	Kombinationer af lægemidler
EP2964120A4 (en)	2016-11-02	ILIAKALVERBINDER
PL2928870T3 (pl)	2020-09-21	Ligandy receptora neurotensyny
SMT201700009B (it)	2017-03-08	Modulatori del recettore x del fegato
DK3010895T3 (da)	2017-11-20	Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK2965026T3 (da)	2019-10-28	Generering af slushice
SMT201600374B (it)	2016-11-10	Modulatori del recettore x del fegato
EP3042244A4 (en)	2016-08-10	TONER
DK2991543T3 (da)	2019-09-02	System til visualisering af kropsområder
UA27558S (uk)	2014-08-11	Лінза
DK3052931T3 (da)	2023-10-30	Fremgangsmåde til overførsel af opslæmning
DK3082642T3 (da)	2021-11-15	Fiksering af protesetænder